Merck/Vical
Sign licensing agreement to develop vaccines for the prevention of human infectious diseases, Vical announces June 12. The vaccines will incorporate Vical's Gene Therapeutics technology, in which gene sequences from viruses are used to stimulate the production of antibodies. The three-year agreement includes undisclosed yearly research funding, milestone payments, option and license fees and royalty payments on sales of products resulting from the agreement. The agreement is the first covering San Diego-based Vical's Gene Therapeutics. The firm also has development agreements with Burroughs Wellcome and Oclassen.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.
Denmark is shaking up clinical trial timelines with a new process for reviewing applications for early-phase mono-national trials that is twice as fast as the standard timelines in the EU and the UK.
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.